Interpreting Diabetic Retinal Outcomes After GLP ‐1 Receptor Agonist and Tirzepatide Initiation: Clinical Evidence and Its Limits

AIMS: Reports of diabetic retinopathy after potent glucose-lowering treatment create uncertainty for clinicians, particularly when studies measure different outcomes in patients with different baseline retinal disease. This review examines diabetic retinal outcomes after glucagon-like peptide-1 receptor agonist or tirzepatide initiation. MATERIALS AND METHODS: This critical narrative review uses targeted, non-systematic study selection. It distinguishes disease onset or progression from detection, treatment use and subsequent visual function. RESULTS: The SUSTAIN-6 retinopathy-complication signal remains clinically relevant; post hoc associations with early glycated haemoglobin reduction do not establish causal mediation. Contemporary cohorts report differing associations across baseline retinal strata, comparators and endpoints. Positive signals should be presented alongside their absolute event proportions and limitations, rather than dismissed because observational adjustment is imperfect. Conversely, non-significant results do not establish equivalence or class-wide safety. CONCLUSIONS: Current guidance supports establishing retinal status and coordinating diabetes and eye care during treatment intensification. The implications differ between patients with recent screening and no known retinopathy, established non-proliferative disease, and active sight-threatening disease or recent retinal treatment. No universal safe rate of glycated haemoglobin decline or retinal-protective titration regimen has been established. Future studies should align eligibility and treatment initiation, distinguish incident disease from progression, and use scheduled retinal assessments. A comparison between two specific medicines can inform treatment choice but cannot exclude risks shared by both.